Changes in syndecan-1 expression are associated with attenuated biosynthesis of Osteoprotegerin and osteoclast formation, identifying tumor-derived syndecan-1 as a novel positive regulator of osteoclastogenesis and a new player in the tumor–bone dialog [79]. The gene discussed is SDC1; the disease is neoplasm.